Selenium and lung cancer: a systematic review and meta analysis.

<h4>Background</h4>Selenium is a natural health product widely used in the treatment and prevention of lung cancers, but large chemoprevention trials have yielded conflicting results. We conducted a systematic review of selenium for lung cancers, and assessed potential interactions with...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Heidi Fritz, Deborah Kennedy, Dean Fergusson, Rochelle Fernandes, Kieran Cooley, Andrew Seely, Stephen Sagar, Raimond Wong, Dugald Seely
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2011
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/74f86b13160443a7bd82e0c80aacbbba
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:74f86b13160443a7bd82e0c80aacbbba
record_format	dspace
spelling	oai:doaj.org-article:74f86b13160443a7bd82e0c80aacbbba2021-11-18T07:34:59ZSelenium and lung cancer: a systematic review and meta analysis.1932-620310.1371/journal.pone.0026259https://doaj.org/article/74f86b13160443a7bd82e0c80aacbbba2011-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22073154/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Selenium is a natural health product widely used in the treatment and prevention of lung cancers, but large chemoprevention trials have yielded conflicting results. We conducted a systematic review of selenium for lung cancers, and assessed potential interactions with conventional therapies.<h4>Methods and findings</h4>Two independent reviewers searched six databases from inception to March 2009 for evidence pertaining to the safety and efficacy of selenium for lung cancers. Pubmed and EMBASE were searched to October 2009 for evidence on interactions with chemo- or radiation-therapy. In the efficacy analysis there were nine reports of five RCTs and two biomarker-based studies, 29 reports of 26 observational studies, and 41 preclinical studies. Fifteen human studies, one case report, and 36 preclinical studies were included in the interactions analysis. Based on available evidence, there appears to be a different chemopreventive effect dependent on baseline selenium status, such that selenium supplementation may reduce risk of lung cancers in populations with lower baseline selenium status (serum<106 ng/mL), but increase risk of lung cancers in those with higher selenium (≥ 121.6 ng/mL). Pooling data from two trials yielded no impact to odds of lung cancer, OR 0.93 (95% confidence interval 0.61-1.43); other cancers that were the primary endpoints of these trials, OR 1.51 (95%CI 0.70-3.24); and all-cause-death, OR 0.93 (95%CI 0.79-1.10). In the treatment of lung cancers, selenium may reduce cisplatin-induced nephrotoxicity and side effects associated with radiation therapy.<h4>Conclusions</h4>Selenium may be effective for lung cancer prevention among individuals with lower selenium status, but at present should not be used as a general strategy for lung cancer prevention. Although promising, more evidence on the ability of selenium to reduce cisplatin and radiation therapy toxicity is required to ensure that therapeutic efficacy is maintained before any broad clinical recommendations can be made in this context.Heidi FritzDeborah KennedyDean FergussonRochelle FernandesKieran CooleyAndrew SeelyStephen SagarRaimond WongDugald SeelyPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 11, p e26259 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Heidi Fritz Deborah Kennedy Dean Fergusson Rochelle Fernandes Kieran Cooley Andrew Seely Stephen Sagar Raimond Wong Dugald Seely Selenium and lung cancer: a systematic review and meta analysis.
description	<h4>Background</h4>Selenium is a natural health product widely used in the treatment and prevention of lung cancers, but large chemoprevention trials have yielded conflicting results. We conducted a systematic review of selenium for lung cancers, and assessed potential interactions with conventional therapies.<h4>Methods and findings</h4>Two independent reviewers searched six databases from inception to March 2009 for evidence pertaining to the safety and efficacy of selenium for lung cancers. Pubmed and EMBASE were searched to October 2009 for evidence on interactions with chemo- or radiation-therapy. In the efficacy analysis there were nine reports of five RCTs and two biomarker-based studies, 29 reports of 26 observational studies, and 41 preclinical studies. Fifteen human studies, one case report, and 36 preclinical studies were included in the interactions analysis. Based on available evidence, there appears to be a different chemopreventive effect dependent on baseline selenium status, such that selenium supplementation may reduce risk of lung cancers in populations with lower baseline selenium status (serum<106 ng/mL), but increase risk of lung cancers in those with higher selenium (≥ 121.6 ng/mL). Pooling data from two trials yielded no impact to odds of lung cancer, OR 0.93 (95% confidence interval 0.61-1.43); other cancers that were the primary endpoints of these trials, OR 1.51 (95%CI 0.70-3.24); and all-cause-death, OR 0.93 (95%CI 0.79-1.10). In the treatment of lung cancers, selenium may reduce cisplatin-induced nephrotoxicity and side effects associated with radiation therapy.<h4>Conclusions</h4>Selenium may be effective for lung cancer prevention among individuals with lower selenium status, but at present should not be used as a general strategy for lung cancer prevention. Although promising, more evidence on the ability of selenium to reduce cisplatin and radiation therapy toxicity is required to ensure that therapeutic efficacy is maintained before any broad clinical recommendations can be made in this context.
format	article
author	Heidi Fritz Deborah Kennedy Dean Fergusson Rochelle Fernandes Kieran Cooley Andrew Seely Stephen Sagar Raimond Wong Dugald Seely
author_facet	Heidi Fritz Deborah Kennedy Dean Fergusson Rochelle Fernandes Kieran Cooley Andrew Seely Stephen Sagar Raimond Wong Dugald Seely
author_sort	Heidi Fritz
title	Selenium and lung cancer: a systematic review and meta analysis.
title_short	Selenium and lung cancer: a systematic review and meta analysis.
title_full	Selenium and lung cancer: a systematic review and meta analysis.
title_fullStr	Selenium and lung cancer: a systematic review and meta analysis.
title_full_unstemmed	Selenium and lung cancer: a systematic review and meta analysis.
title_sort	selenium and lung cancer: a systematic review and meta analysis.
publisher	Public Library of Science (PLoS)
publishDate	2011
url	https://doaj.org/article/74f86b13160443a7bd82e0c80aacbbba
work_keys_str_mv	AT heidifritz seleniumandlungcancerasystematicreviewandmetaanalysis AT deborahkennedy seleniumandlungcancerasystematicreviewandmetaanalysis AT deanfergusson seleniumandlungcancerasystematicreviewandmetaanalysis AT rochellefernandes seleniumandlungcancerasystematicreviewandmetaanalysis AT kierancooley seleniumandlungcancerasystematicreviewandmetaanalysis AT andrewseely seleniumandlungcancerasystematicreviewandmetaanalysis AT stephensagar seleniumandlungcancerasystematicreviewandmetaanalysis AT raimondwong seleniumandlungcancerasystematicreviewandmetaanalysis AT dugaldseely seleniumandlungcancerasystematicreviewandmetaanalysis
_version_	1718423228582461440

Selenium and lung cancer: a systematic review and meta analysis.

Ejemplares similares